- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Citing Decline in Glyphosate-Based Product Sales, Bayer Lowers Yearly Outlook
Company now expects around $53 billion in sales for 2023.
The Bayer Group revealed that its full-year outlook has been lowered, with a significant dive in glyphosate-based product sales. According to a company press release, adjustments now forecast an estimated $53 billion in sales before taxes, crediting information from its 2022 average monthly exchange rates.
Previously, the organization alluded to lowering the outlook when communicating its first quarter results. It also stated that a combination of decline in prices and lower volumes due to channel de-stocking increased pressure on making the decision. Reportedly, Bayer expects a negative group net income of an estimated $2.2 billion dollars for the second quarter of the year, with detailed results being released early next month.
Reference: Bayer lowers full-year outlook. Bayer. July 24, 2023. Accessed July 26, 2023. https://www.bayer.com/media/en-us/bayer-lowers-full-year-outlook/
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
